Research at the Center for Drug Safety and Immunology 

The Center for Drug Safety and Immunology (CDSI) at Vanderbilt University Medical Center (VUMC) specializes in research investigating immunologically mediated adverse drug reactions (IM-ADR). CDSI studies the genetic, molecular, and cellular signals that lead to the development of IM-ADRs to predict and prevent these life-threatening reactions. We are pursuing novel research strategies to understand why these adverse drug reactions occur in specific patients and have several ongoing research studies focusing on IM-ADRs. 

One of our current studies includes a first-of-its-kind multicenter clinical trial to determine whether two therapeutic interventions - cyclosporine and etanercept - will improve short-term outcomes associated with Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) over the standard of care. This trial, the North American Therapeutics In Epidermal Necrolysis Syndrome (NATIENS), is actively recruiting and is led by CDSI founder and director, Dr. Elizabeth Phillips

CDSI-led studies

Additional research initiatives spearheaded by CDSI faculty include: 

External Collaborations

CDSI also partners with several other investigators and institutions on ongoing studies to elucidate the mechanisms that drive IM-ADRs. Some of these essential partnerships include: 

Completed studies

Recent studies completed by CDSI in collaboration with our research partners include: